title: Nw-hydroxy-L-arginine as a novel ethnic specific indicator of estrogen-negative breast cancer.
abstract: As a heterogeneous disease, breast cancer can be divided into distinct subtypes. Among the two major subsets of estrogen receptor-negative (ER-) and ER-positive (ER+) tumors, the ER-is a more aggressive subtype, more difficult to treat, has greater ethnic disparity concerns, worse prognosis, and almost twice the risk of mortality. We provide here a fundamental delineation of Nw-hydroxy-L-arginine as a sensitive and reliable ethnic specific indicator for ER-breast cancer early-prognosis (United States provisional patent application number 62232816).
authors: Department of Pharmaceutical Sciences, College of Pharmacy, University of New England, Portland, ME, 04103, USA. smohan@une.edu.
authors: Srinidi
authors: 0000-0003-2895-8213
authors: S
authors: Mohan
authors: Department of Pharmaceutical Sciences, College of Pharmacy, University of New England, Portland, ME, 04103, USA.
authors: Nancy
authors: N
authors: Moua
authors: Department of Pharmaceutical Sciences, College of Pharmacy, University of New England, Portland, ME, 04103, USA.
authors: Lisa
authors: L
authors: Harding
mesh_terms: D001120:Arginine / Q000031:analogs & derivatives* / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000208:ethnology* / Q000378:metabolism*; D005260:Female; D006801:Humans; D061986:MCF-7 Cells; D011960:Receptors, Estrogen
chemical_list: D014408:Biomarkers, Tumor; D011960:Receptors, Estrogen; D001120:Arginine
keywords: Breast cancer; Estrogen-negative; Inflammatory nitric oxide synthase; N w-hydroxy-L-arginine